Encompass Health Corporation (EHC)
Valuation Overview•Is Encompass Health Corporation Overvalued or Undervalued?
Trading at a discount across both intrinsic cash flow and relative peer multiples, indicating a strong margin of safety.
Moderate quality score of 68/100, reflecting stable operating margins and manageable leverage.
Analysts remain bullish, forecasting further upside expansion with consensus targets suggesting solid gains.
Verdict: Solid fundamental quality, though profitability presents a headwind.
Wall Street is highly bullish, projecting significant upside. This is paired with healthy capital returns, driven predominantly by aggressive share repurchases.
EHC demonstrates strong business quality with robust profitability and healthy margins. This is paired with a moderately leveraged but stable balance sheet.
The company demonstrates solid revenue growth (10.9% 3Y CAGR) paired with highly explosive earnings growth (27.1% EPS 3Y CAGR). The company maintains healthy operational efficiency with a 16.8% operating margin.
| Financial Metric | Trend (12Q) | Latest Qtr | 1Y Growth | 3Y CAGR | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| Revenue | $1.6B | +10.5% | +10.9% | +10.7% | +6.7% | |
| EBITDA | $319.6M | — | +16.5% | — | — | |
| Net Income | $194.5M | +24.2% | +27.8% | — | +12.0% | |
| EPS (Diluted) | $1.77 | +24.2% | +27.1% | +14.2% | +11.2% | |
| Free Cash Flow | -$141.2M | +21.9% | +53.4% | +8.2% | — |
| Metric | TTM | 3Y Avg | 5Y Avg | 10Y Avg |
|---|---|---|---|---|
| Gross Margin | 58.8% | 59.5% | 52.3% | 74.2% |
| Operating Margin | 16.8% | 23.3% | 20.1% | 18.4% |
| Net Margin | 10.0% | 8.5% | 8.4% | 7.8% |
| FCF Margin | 2.8% | 6.6% | 5.3% | 7.3% |
| Quarter | EPS Est. | EPS Act. | Surprise | EPS | Rev |
|---|---|---|---|---|---|
| Q2'26Latest | $1.51 | $1.60 | +6.0% | ||
| Q1'26 | $1.29 | $1.46 | +13.2% | ||
| Q4'25 | $1.19 | $1.23 | +3.4% | ||
| Q3'25 | $1.23 | $1.40 | +13.8% | ||
| Q2'25 | $1.19 | $1.37 | +15.1% | ||
| Q1'25 | $1.05 | $1.17 | +11.4% | ||
| Q4'24 | $0.94 | $1.03 | +9.6% | ||
| Q3'24 | $1.01 | $1.11 | +9.9% |
Total return is -17.5% (1Y), lagging the benchmark by -42.5%
| Period | Total Return | vs S&P 500 (Alpha) | Dividend Contribution |
|---|---|---|---|
| YTD | -7.5% | -16.8% | — |
| 1Y | -17.5% | -42.5% | +0.6% |
| 3YCAGR | +15.7% | -3.8% | +3.1% |
| 5YCAGR | +9.9% | -2.9% | +5.7% |
| 10YCAGR | +12.8% | -0.8% | — |
The S&P 500 is at 31.3x trailing P/E — Expensive relative to historical averages.
Quick answers to common questions about Encompass Health Corporation (EHC) valuation, health, and returns.
Encompass Health Corporation is estimated to be undervalued under our discounted cash flow framework. relative multiples indicate the stock is Cheap versus peers compared to industry peers. undervalued (implying +56.8% upside to DCF intrinsic value of $153.73)
Encompass Health Corporation has multiple valuation anchors: DCF Intrinsic Value: $153.73 | Peer Relative Fair Value: $131.45 | Wall Street Analyst Target: $146.00 (implying +48.9% upside). A convergence of these signals offers higher conviction.
Encompass Health Corporation displays good financial health with a composite quality score of 68/100, supported by a Altman Z-Score of 2.6 (grey zone), Piotroski F-Score of 9/9, Return on Invested Capital (ROIC) of 13.9%.
Encompass Health Corporation pays a 0.7% dividend yield, covered by a 13% payout ratio with 2 years of growth, supplemented by a 1.6% buyback yield.
Encompass Health Corporation's current growth trajectory is Stable. The company achieved +10.5% 1Y revenue growth and +24.2% 1Y EPS growth, compared to its 3Y revenue CAGR of +10.9%.
Wall Street consensus is Buy based on 26 analysts, beating EPS expectations in 100% of recent quarters with a 15-quarter streak. The consensus price target represents a +48.9% change from current levels.
Investment risks for Encompass Health Corporation include: -26.2% 1-year max drawdown. Volatility risk is characterized by a beta of 0.24x.
No. These computations are purely quantitative model outputs for informational purposes. They do not account for qualitative management shifts or macro events. Always consult a licensed RIA before buying or selling shares.
Disclaimer: This page is for informational purposes only and does not constitute financial advice. All valuation models, scores, and target estimates are automated computations under stated assumptions and should not be relied upon as the sole basis for any investment decision.